Skip to content

OCRA Financial Stewardship

Financial Stewardship

Preserving The Public Trust

Transparency, Accountability, Stewardship

When you donate to OCRA, you can be sure your money is handled responsibly. By ensuring rigorous accountability, financial transparency, and meticulous stewardship of our donors’ funds, OCRA has earned the highest possible rating from Charity Navigator and a Gold rating from Guidestar. We also meet the stringent Standards for Charity Accountability set forth by the Better Business Bureau’s Wise Giving Alliance.

 

Please explore this page to view our financial statements and policies.

Financial Statements

Ovarian Cancer Research Alliance is a 501(c) 3 non profit organization. Our financial documents are public and available for viewing below.

Financial Statements from Ovarian Cancer Research Alliance:

Financial Statements from the former Ovarian Cancer Research Fund:

Financial Statements from the former Ovarian Cancer National Alliance:

Policies

A 501(c)(3) organization, Ovarian Cancer Research Alliance receives funding from individual donors, foundations, corporations, and cause-marketing initiatives. Individual solicitations, direct mail, fundraising events, grant proposals, sponsorships, product sales, and special projects secure these funds.

Our mission is to remain objective in providing information to the ovarian cancer community; we do not endorse any particular treatment, therapy, clinical trial or product.

Ovarian Cancer Research Alliance is committed to:

  • Ensuring that fundraising complies with all applicable federal and state regulations, including appropriate registrations, annual filings, and audits to comply with the Internal Revenue Code;
  • Providing the public with access to its most recent financial reports and filings;
  • Maintaining the confidentiality of donors’ information and ensuring any disclosures comply with all applicable laws;
  • Accepting contributions from sources such as individuals, foundations, and for-profit institutions while ensuring that the positions of Ovarian Cancer Research Alliance on policy issues are never unduly or improperly influenced by contributors.

Conflict of Interest Statement — Industry Partners

  • Corporate partners including industry do not shape OCRA’s agenda, research, or advocacy.
  • In 2023, industry partners represented 8% of OCRA’s overall revenue.
  • If an industry partner sponsors an OCRA program, grant, or educational materials, it is publicly acknowledged and the supporting company has no editorial or strategic input.
  • Any reference to a specific commercial product or service does not constitute or imply an endorsement by OCRA of the product or service or its producer or provider. The views and opinions expressed in any referenced document or on any referenced website do not necessarily reflect those of OCRA.

Related Topics

OCRA-Funded Study Provides Clear New Evidence That Opportunistic Salpingectomy Drastically Reduces Risk of Ovarian Cancer

OCRA-Funded Study Provides Clear New Evidence That Opportunistic Salpingectomy Drastically Reduces Risk of Ovarian Cancer

A new study published February 2 in JAMA Network Open provides the clearest evidence to date that opportunistic salpingectomy—the removal of the fallopian tubes during another gynecologic surgery—can dramatically reduce the risk of ovarian cancer. Led by a B.C.-based international collaboration known as the Ovarian Cancer Observatory, the study found that people who underwent opportunistic … Continued

Read more

(Webinar) – Ask the Experts: Gynecologic Sarcoma

(Webinar) – Ask the Experts: Gynecologic Sarcoma

Watch Now: Ask the Experts Webinar on Gynecologic Sarcoma On January 28, 2026, Ovarian Cancer Research Alliance (OCRA) hosted a live Ask the Experts: Gynecologic Sarcoma webinar with Matthew Hemming, MD, PhD. Moderated by Liza Lundgren, LCSW, OCRA’s Director of Education, this free session featured a live discussion and audience Q&A focused on gynecologic sarcoma research, … Continued

Read more

Action Alert: Urge Congress to Pass Final Bill on Cancer Research Funding and Early Detection

Action Alert: Urge Congress to Pass Final Bill on Cancer Research Funding and Early Detection

The Congressional Appropriations Committees have released a combined FY2026  Defense/Labor, Health and Human Services bill—and it includes several critical investments and policy provisions that would significantly strengthen the federal response to ovarian and other gynecologic cancers. This bill represents meaningful progress for our community, but it is not final. Congress must act swiftly to advance and … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.